U.S. Stem Cell, Inc.(USRM)

Research Snapshot

U.S. Stem Cell, Inc. (USRM) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 50.0% across the available one-year price window (Jun 20, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -59.1%, EPS growth of +32.4%, a dividend yield of 0.0%. What stands out right now is revenue -59.1%, EPS +32.4%, free cash flow +71.2% with operating margin -2096.9% and ROIC 29.9%. Valuation is more restrained than many high-expectation growth names at price/sales 0.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines USRM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.